|
|
|
Amorfix Life Sciences (Toronto), a company focused on diagnostics and treatments for brain wasting diseases, announced that Joseph Beckman, Ph.D., will join the Company's Scientific Advisory Board. Dr. Beckman is an expert in Amyotrophic Lateral Sclerosis (ALS) disease and the role of superoxide dismutase-1 (SOD1) in this disease. Amorfix's therapeutic program for ALS targets SOD1. http://www.amorfix.com |
|
发表于 2007-8-2 13:23:21